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Abstract
Case presentation: We report for the first time a synchronous papillary and follicular thyroid carcinoma in a 12-
year-old girl presenting with a large (5 cm diameter) left thyroid nodule, an increased left and right upper pole
technetium tracer uptake at scintigraphy and hyperthyroidism. The uptake at the right lobe was explained by the
crossing of the left nodule to the right site of the neck at Computed Tomography (CT) scanning.
Background: Although thyroid nodules are less common in children than in adults, there is more vigilance
required in children because of the higher risk of malignancy. According to literature, about 5% of the thyroid
nodules in adults are malignant versus 20–26% in children. The characteristics of 9 other pediatric cases with a
differentiated thyroid carcinoma presenting with a toxic nodule, which have been reported during the last 20 years,
are summarized. A nodular size of more than 3.5 cm and female predominance was a common finding.
Conclusions: The presence of hyperthyroidism in association with a hyperfunctioning thyroid nodule does not rule
out thyroid cancer and warrants careful evaluation, even in the absence of cervical lymph node invasion.
Keywords: Hyperthyroidism, Toxic nodule, Follicular thyroid carcinoma, Papillary thyroid carcinoma, Children,
Pediatric
Background
Solitary thyroid nodules are rare in childhood in com-
parison with adulthood, but have a higher risk of malig-
nancy [1]. Up to 26% of the thyroid nodules in children
were found to be malignant [1–3]. Most differentiated
thyroid cancers (DTC) in children are papillary carcin-
oma, which only very rarely (over) produce thyroid hor-
mones, causing subclinical or overt hyperthyroidism [4].
In a recent pediatric cohort study of thyroid nodules,
hyperthyroidism was found in only 5% [5]. The finding
of a hyperfunctioning or hot nodule on scintigraphy in
the context of hyperthyroidism, especially in the absence
of enlarged cervical lymph nodes, is usually reassuring,
as in most cases a benign follicular adenoma is diag-
nosed [5–7].
We additionally reviewed the previously reported DTC
in children and adolescents with a hyperfunctioning thy-
roid nodule associated with hyperthyroidism, also called
toxic nodule, to look for common characteristics and
potential risk factors for malignancy. A literature search
on Pubmed and Web of Science was performed in the
English literature in a period from January 2009, when
most laboratories were using a third generation TSH
assay, until December 2019. The search terms used were
“hyperthyroidism and thyroid carcinoma”, “toxic nod-
ule”, “hyperfunctioning nodule and thyroid carcinoma”
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in conjunction with either “children” or “pediatric”. In-
clusion criteria were detailed case descriptions of chil-
dren aged below 16 years old with a clinical and
biological hyperthyroidism and an underlying differenti-
ated thyroid carcinoma documented at histological
examination. Finally, 8 articles describing 9 cases were
selected. Clinical characteristics, biological, imaging and
histological results and initial treatment of these 9
pediatric patients are summarized in Table 1.
Overview of previously reported case reports of DTC in
children with a toxic nodule [8–15]
All described patients were female except one. Age at
presentation varied between a minimum age of 2 months
and a maximum age of 16 years (median 11 years). The
severity of the hyperthyroidism is not always mentioned,
but FT4 concentrations up to 3 times the upper limit
with less elevated FT3 concentrations were reported.
Right as well as left sided localisation of the nodule was
seen, while the longest diameter of the nodule ranged
from 35 to 50 mm. Suppressed activity in surrounding
tissue at scintigraphic evaluation was noted in 8 cases. In
four cases a follicular variant of a papillary thyroid car-
cinoma was found, while in the others either a papillary
thyroid carcinoma or a follicular carcinoma was present
(Table 1).
Case presentation
In a 12-year-old female, presenting with a painless neck
swelling since one month, a 5 cm long, non-tender but
firm nodule in the left thyroid lobe was detected at phys-
ical examination. There was no palpable cervical lymph-
adenopathy. Slight tachycardia (pulse rate 95/min), but
no exophthalmos was present. The patient reported
intermittent sore throat, increasing nervousness and a 2
kg weight loss in the last several months. There was no
history of radiation exposure. Her mother had recently
undergone surgery for a multi-nodular goitre. There was
no family history of cancer or intestinal polyps.
Thyroid function tests showed an elevated FT4 (51
pmol/L or 39.6 pg/mL) and thyroglobulin concentration
(435 μg/L) and a decreased TSH (< 0.005mU/L) concen-
tration.1 Serum anti-thyroglobulin, anti-thyroidperoxidase
and anti-TSH receptor antibodies were undetectable.
Doppler ultrasound showed a normal right lobe as well as
a sharp defined hypervascular solid multilobular mass
(longest diameter 53mm) with cystic components with
microcalcifications in the left lobe. A 99mTechnetium scin-
tigraphy (Fig. 1) showed a global, but heterogeneous hy-
perfunctioning thyroid gland with excessive uptake at the
upper left lobe and upper right lobe. A right tracheal
deviation by the left thyroid mass, but no cervical or medi-
astinal lymphnodes or lung masses, was seen on the CT
scan of neck and thorax (Fig. 2). Subsequently, a large
toxic adenoma crossing the midline was diagnosed,
explaining the tracer uptake in the right upper pole region.
Fine needle biopsy was refused by the patient and a left
thyroidectomy was proposed. The patient underwent a left
hemithyroidectomy after 2months of methimazole ther-
apy, which resulted in normalized thyroid function in one
month’s time. Histological examination of the left lobe
showed two separated morphologically distinct neoplastic
lesions arising in what appeared to be a multinodular
goitre. The largest lesion (measuring 2.9 cm) showed a fol-
licular growth pattern with cytonuclear atypia, multiple
foci of intracapsular vascular invasion and some foci of
capsular invasion. Separated from this lesion by a couple
of millimetres, a second neoplastic lesion was seen. This
was non-encapsulated and infiltrative and had a papillary
and follicular growth pattern with cytonuclear features of
a papillary thyroid carcinoma (nuclear clearing, nuclear in-
clusions and grooves). The non-encapsulated, infiltrative
neoplastic lesion with papillary architecture and cytomor-
phology showed aberrant apical and strong HBME immu-
nohistochemical staining, whereas the adjacent lesion with
follicular growth pattern was completely negative for
HBME. Therefore, based on the morphology and immu-
nohistochemistry, a diagnosis of a synchronous minimally
invasive follicular thyroid carcinoma (with multifocal cap-
sular invasion and angioinvasion) and a non-encapsulated,
infiltrative (classical type) papillary thyroid carcinoma of
the left lobe was made (Fig. 3). Consequently, total thy-
roidectomy was performed.
Genetic testing on the surgical specimen was negative
for BRAF and NRAS mutations and RET/PTC rearrange-
ments. Results of TSHR gene, GNAS gene and PTEN
gene analysis were normal.
Discussion
Hyperfunctioning nodules at thyroid scintigraphy, also
called hot nodules, can present with or without hyperthy-
roidism. In the latter case, these nodules are also described
as toxic nodules in literature. In the previously reported
nine pediatric cases of DTC with associated hyperthyroid-
ism and a hot nodule at scintigraphy, follicular carcin-
omas, papillary carcinomas as well as follicular variants of
papillary thyroid carcinoma were diagnosed. We report
for the first time a synchronous papillary-follicular thyroid
carcinoma in female adolescent presenting with a toxic
nodule. In our case as well as in the previously reported
pediatric cases, the nodules were found to be greater than
3 cm in diameter, suggesting that clinical hyperthyroidism
does not appear until the nodule is at least 3 cm in
diameter. When comparing with non-hyperfunctioning
nodules, thyroid nodules in hyperthyroid adolescents were
1Reference rate: FT4 12.0–22.0 pmol/L, thyroglobulin concentration
0.2–70.0 μg/L, TSH 0.70–6.4 mU/L
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found to have more compressive signs and a greater nod-
ule size, and are mostly diagnosed as follicular adenomas
(toxic adenoma) [5, 16].
The major goal of the diagnostic evaluation of thyroid
nodules is to differentiate thyroid cancers, especially ag-
gressive lesions, from benign adenomas. In the initial
work-up of a thyroid nodular lesion, thyroid function
tests are usually performed. The American Thyroid As-
sociation (ATA) Taskforce recommends that patients
who have a thyroid nodule larger than 1 to 1.5 cm in any
dimension, should have a serum thyrotropin (TSH)
measurement [17]. If hyperthyroidism is associated with
a nodule on ultrasound, a scintiscan is the next logical
step to document the hyperfunctioning of the nodule,
especially when thyroid stimulating immunoglobulines
are absent. In toxic adenoma, the typical scintigraphic
finding is a hot pattern in the nodule with the remnant
thyroid tissue showing a severely decreased or absent
uptake [18]. In our case no complete suppression was
found, while in the other pediatric cases both complete
and incomplete scintigraphic suppression patterns were
reported. An incomplete suppression pattern was seen
as a risk factor for DTC by Niedziela et al. [19] in his
series of 31 children with a hyperfunctioning nodule.
The prevalence of malignancy in a hot nodule in adults
has been estimated at 3.1% [20]. Histological outcome stud-
ies in children with a toxic nodule are very limited. No ma-
lignancy was detected in 6 Italian hyperthyroid pediatric
patients with a solitary toxic nodule at surgery [5]. In an
American study of 4 children with a hot or warm nodule
and persisting T3 hyperthyroidism, no malignancy was
found after partial thyroidectomy [18], while in another
study of 2 hyperthyroid adolescents a follicular carcinoma
was found in one female [21]. However, in a more recent
study of 15 Polish children with hyperthyroidism and a hy-
perfunctioning nodule at scintigraphy, a DCT was diag-
nosed in 2 children after surgery [22]. In none of the
reported adult or pediatric cases a simultaneous papillary
and follicular carcinoma in a hot nodule was described.
The simultaneous occurrence of different types of thyroid
cancer in a single patient is very rare. Although there are
noticeable reports about synchronous papillary cancer, the
reports of simultaneous papillary and follicular cancer are
actually rare [23]. This simultaneous thyroid tumor presen-
tation has been described as coincidental in the literature as
no common gene mutation for the pathogenesis of the dif-
ferent tumor types of the thyroid has been found. Mixed
tumors however can occur as part of familial cancer syn-
dromes. Cowden’s syndrome was excluded in our patient
by genetic analysis, while no signs of Carney’s complex
were present. Fine needle aspiration (FNA) biopsy is con-
sidered to be the most accurate procedure to identify malig-
nant nodules, but is generally not advised in hot nodules.
First, their larger size might easily result in false negative re-
sults. Second, hot nodules have lower likelihood of finding
malignancy compared to cold nodules and third, there are
histological difficulties in differentiating follicular adenoma
from follicular thyroid carcinoma.
Contrary to guidelines for adults, the current recommen-
dation for treatment of hyperfunctioning nodules in chil-
dren is surgical resection rather than radio iodine treatment
[11, 24]. Surgery is even more preferred when there are
signs of compression, which is a common finding in hyper-
functioning nodules since they are larger in most cases than
non-functional nodules [25]. Because of the absence of clin-
ical (male gender, age < 10 years, family history of thyroid
cancer) and ultrasound (irregular margins) risk factors, as
Fig. 1 Scintigraphic image showing a global but heterogeneous
hyperfunctioning thyroid gland with excessive uptake at upper left
lobe and upper right lobe
Fig. 2 CT image showing a right tracheal deviation by a left
thyroid mass
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well as the absence of enlarged cervical lymph nodes, medi-
astinal and lung invasion at CT scanning, DCT was initially
not suspected in this case and a hemithyroidectomy was
performed with a the preoperative diagnosis of a large toxic
adenoma. In the presence of a size of more than 4 cm and
an intense internal vascularisation (and calcifications in the
nodule), an initial total thyroidectomy could have been jus-
tified, as suggested by Deluca et al. [26]. On the other hand,
a family history of multinodular goitre and the absence of
cervical and lung invasion was assessed as a reassuring fea-
ture in our case, favouring a left hemithyroidectomy. We
first treated our patient with methimazole, as patients with
overt hyperthyroidism due to a hyperfunctioning nodule
should be euthyroid prior to the surgical procedure [25]. In
all reported cases, euthyroidism was observed relatively
quickly after medical treatment, as observed in our case.
Somatic mutations of the TSHR and GNAS1 gene have
been detected in adolescents presenting with autono-
mous functioning benign thyroid nodule as well as
thyroid carcinoma with or without associated hyperthy-
roidism [8, 14, 22]. In one study, in 17 of 29 of benign
hyperfunctioning nodules somatic TSHR mutations were
found, while only one of the 4 studied DCT a mutation
was found. Surgical specimen examination in our case
was negative for BRAF and NRAS mutations and RET/
PTC rearrangements. Increased malignancy rate of
hyperfunctioning nodules was found not to be associated
with BRAF, NRAS mutations and PAX8/PPARG and
RET/PTC rearrangements [22].
Conclusion
In conclusion, our case illustrates the difficulty to accurately
determine the risk of DTC in hyperthyroid adolescents pre-
senting with a toxic nodule and provides histological evi-
dence that a large thyroid carcinoma can be composed of
both a follicular and papillary carcinoma.
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